Schiff Advises Moleculin Biotech, Inc. on its $78M Public Offering
Schiff Hardin LLP advised Moleculin Biotech, Inc. in connection with its public offering of 16,414,736 shares of common stock for gross proceeds of approximately $78 million.
Schiff Hardin LLP advised Moleculin Biotech, Inc. in connection with its public offering of 16,414,736 shares of common stock for gross proceeds of approximately $78 million. Moleculin is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses. The offering closed February 10, 2021.
Smart In Your World
Your goals define our mission. Whether an immediate need or a long-term objective, ArentFox Schiff helps you reach your full potential. As industry insiders, we partner with you to develop practical business strategies and sophisticated legal solutions to achieve today’s targets and anticipate tomorrow’s problems. We get you across the finish line.
Contacts
-
Contact:
Nathan Carlile, Head of Firmwide Communications
- Related Industries
- Related Practices